Hims vs Ro
Ro costs $50 less a month.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Hims
Best for: knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC
Visit Hims →
Ro
Best for: knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC
Visit Ro →If you are choosing between Hims and Ro, the first difference is cost: Ro is $50 a month cheaper at the entry price. Hims leads our six-part score, 6.8 to 6.7. One of the two has an FDA warning letter on record, covered below.
Hims vs Ro price
Ro is the cheaper way in: $149 a month against $199 a month at Hims. That is $50 less each month (25% lower), or about $600 over a year of treatment.
Medications and formats
Hims and Ro do not overlap on medication; only Hims lists semaglutide and tirzepatide; only Ro lists orforglipron.
On format, Hims prices compounded injections and brand-name pens, while Ro prices brand-name pens.
Where each one treats patients
Hims lists 50 states, and Ro does not publish where it ships.
Pricing
Hims
Brand Zepbound from $299/mo medication-only; requires Hims Weight Loss Membership ($149/mo)
Ro
Additional membership fees apply
What each price covers
Hims' price also covers the medication itself, which Ro does not claim.
Ro's price also covers the clinician visit, lab work and coaching, which Hims does not claim.
Hims is silent on shipping and lab work.
Ro is silent on shipping.
That matters most for the drug: unless Ro confirms otherwise, budget for medication on top of its listed price.
Hims
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
Ro
Covered by the monthly price
Medication
Charged on top
Clinician visits
In the price
Shipping
Not stated
Lab work
In the price
Coaching
In the price
Where each one scores higher
Overall, Hims scores 6.8 and Ro 6.7 out of 10.
Hims is stronger on effectiveness (10.0 vs 8.0) and accessibility (10.0 vs 5.0).
Ro is stronger on value (5.0 vs 3.0), trust & safety (8.0 vs 7.0) and support (5.5 vs 3.0).
User experience is within half a point.
Hims
6.8/10
Ro
6.7/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent Hims a warning letter dated September 9, 2025 (letter 716567), and it is still open.
Ro has no FDA warning letter on record with us.
Features & Coverage
| Feature | Hims | Ro |
|---|---|---|
| Starting Price | $199/mo | ✓$149/mo |
| Features | 2 features | ✓7 features |
| States Available | 50 | Not disclosed |
| Compounded | ✓ Yes | — |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | 1 letter | ✓None |
About Hims
Hims is a major men's telehealth brand. Its weight loss offering is compounded semaglutide on a 6-month plan.
Read our full Hims review →About Ro
Foundayo (orforglipron), the new oral GLP-1 from Eli Lilly, joined Ro on April 9 2026 at $149/month for the lowest dose, membership on top. Beside it sit compounded semaglutide and the brand-name pair, Zepbound and Wegovy. No obesity care formulary in the category is more comprehensive. In the US, only a handful of direct-to-patient telehealth companies are larger.
Read our full Ro review →Pros & Cons
Hims
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication
- Serves all 50 states
- Names 4 pharmacies that fill its prescriptions, which most sellers do not
Watch-outs
- Not included in the monthly price: clinician visits, coaching
- The FDA has issued Hims a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Ro
What we like
- Orforglipron costs $149 a month, close to the $149 median for brand-name orforglipron across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes clinician visits, lab work and coaching
- Names Roman Health Pharmacy LLC as the pharmacy that fills its prescriptions, which most sellers do not
- We found no FDA warning letters issued to Ro
Watch-outs
- Not included in the monthly price: medication
- Confirm it serves your state before you start the intake
Our Verdict
Hims wins this one, 6.8 to 6.7, above all for knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC. Ro undercuts it by $50 a month, so if the monthly bill is what decides it, Ro is the pick. Ro fits better if knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC is your priority.
Choose Hims if…
You want knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC and an opening price near $199 a month.
Choose Ro if…
You want knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC and an opening price near $149 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Sesame Care
Oral orforglipron alongside the injectables
From $59/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo
Get started →Found
Tirzepatide at $169/month, 37% below the typical price
From $149/mo
Get started →Hims vs Ro: FAQ
Close alternatives to Hims and Ro
- Hims vs Hers
- Hims vs Noom
- Hims vs Care Bare Rx
- Hims vs Concierge MD LA
- Ro vs Amazon One Medical
- Ro vs LillyDirect Foundayo
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.